SHIRE GETS APPROVAL TO RESUME ADDERALL XR SALES IN CANADA

Shire Pharmaceuticals Group PLC said Canadian regulators have allowed it to resume marketing of hyperactivity treatment Adderall XR, the company's biggest product, following the drug's withdrawal in February amid safety concerns. New data, including cases of sudden death and stroke among Adderall XR users, prompted the suspension in Canada. The same data led US regulators to demand labelling on the product be changed, advising the drug not be used by children or adults with heart defects.

Forbes (http://www.forbes.com/business/feeds/afx/2005/08/24/afx2190362.html)